The lineaments of Ireland's new science strategy are evident in its latest round of research funding, comprising €200 million (US$261 million) of public money, which will fund seven university-industry research centers over the next six years. Industry partners will add another €100 million through a mix of cash and in-kind contributions.
4SC AG could earn up to €96 million (US$125 million) in option and milestone payments arising out of a preclinical drug development deal in inflammatory skin disease with Leo Pharma A/S, as well as double-digit royalties on eventual product sales.
DUBLIN, Ireland – Shares in Elan Corp. plc (NYSE:ELN) rose 5 percent to $11.14 Monday in response to an indicative $11 per-share takeover offer from Royalty Pharma.
DUBLIN, Ireland – Shares in Elan Corp. plc (NYSE:ELNrose 5 percent to $11.14 Monday in response to an indicative $11 per-share takeover offer from Royalty Pharma.
Shares in Gentium SpA fell 20 percent last week on news that the lengthy approval process for defibrotide, a drug for the treatment and prevention of hepatic veno-occlusive disease (VOD) in patients undergoing hematopoietic stem cell transplant, had just become longer.
Following pressure from a group of dissident shareholders, Diamyd Medical AB agreed to return most of its cash to its investors, while retaining a small amount to continue two Phase II trials of its GAD vaccine for the treatment and prevention of Type I diabetes.
The FDA accepted for review a new drug application for lixisenatide, the once-daily glucagon-like peptide-1 (GLP-1) receptor agonist Zealand Pharma A/S has developed in partnership with Sanofi SA, paving the way for a possible U.S. approval in Type II diabetes by early 2014.
Matthias Wymann, the Swiss scientist who discovered the first phosphoinositide 3-kinase (PI3K) inhibitor, is co-founder of a new cancer drug discovery start-up, Piqur Therapeutics AG, which recently completed a seed financing round that will enable it take forward a pipeline of next-generation kinase inhibitors.
Matthias Wymann, the Swiss scientist who discovered the first phosphoinositide 3-kinase (PI3K) inhibitor, is co-founder of a new cancer drug discovery start-up, Piqur Therapeutics AG, which recently completed a seed financing round that will enable it take forward a pipeline of next-generation kinase inhibitors.
